May 8, 2025
A tricky time in markets, bottoming share pricing needs to be picked-up
As volatility is here to stay, enhanced by LPS (loss-per-share) earnings season
Breaking: A drop in jobless claims for the week ending 5/3. Initial filings for unemployment insurance came out at 228,000 for the week, lower than the prior period and below the consensus estimate.
Coming Earnings: BLFS and NTLA 5/8, RGNX on 5/9, EDIT, CLLS and SGMO 5/12, BCLI 5/13
No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief
Never leave an investor uninformed!
April 28, 2025
Newest 4/28/25: NO runway, barely any cash position; No partner, NO clinical data as trial falters yet the salaries and bonuses of CEO and MNGT team are OUTSTANDING and for WHAT?
Newer: Banging the drum for a Ponzi scheme designation (not the first time, maybe the 25th) as share pricing jumps +$0.03 with 3,273 shares traded on 4/25/25 ...
New: On April 11, 2025, Marcum LLP (their accountants) informed Harvard Apparatus Regenerative Technology (OTCQB: HRGN) that Marcum resigned as the Registrant’s independent registered public accounting firm. Also on April 11, 2025, the Registrant, with the approval of the Audit Committee of the Registrant’s Board of Directors, engaged CBIZ CPAs P.C. as the Registrant’s independent registered public accounting firm.
Following a MAJOR question, "WHAT happens to OTCQB: HRGN if the White House and the new head of the SEC starts to "DELIST" Chinese companies???
Under the Holding Foreign Companies Accountable Act, the SEC can ban foreign companies from trading ..."
Wall Street Journal, 4/21/25 ... "Many investors would opt to SELL their stakes in Chinese firms if they are delisted"
May 8, 2025
Those sector equites that have suffered are bounding on positive market news as yesterday, Wednesday’s post: the “sector share pricing bends, blends and ultimately extends to a positive close”
Earnings:
Coming Earnings: RGNX on 5/9
Never leave an investor uninformed!
April 28, 2025
Newest 4/28/25: NO runway, barely any cash position; No partner, NO clinical data as trial falters yet the salaries and bonuses of CEO and MNGT team are OUTSTANDING and for WHAT? Is Beijing, China coming to the rescue again, NOT if President Trump has a say! Newer: Banging the drum for a Ponzi scheme designation (not the first time, maybe the 25th) as share pricing jumps +$0.03 with 3,273 shares traded on 4/25/25 ... Who's buying a falling knife ... fork and spoon after barely if any trading volume for months -- DST Capital? New: On April 11, 2025, Marcum LLP (their accountants) informed Harvard Apparatus Regenerative Technology (OTCQB: HRGN) that Marcum resigned as the Registrant’s independent registered public accounting firm. Also on April 11, 2025, the Registrant, with the approval of the Audit Committee of the Registrant’s Board of Directors, engaged CBIZ CPAs P.C. as the Registrant’s independent registered public accounting firm. Marcum’s LLP had reported the addition of a paragraph expressing substantial doubt about the Company’s ability to continue as a going concern. Following a MAJOR question, "WHAT happens to OTCQB: HRGN if the White House and the new head of the SEC starts to "DELIST" Chinese companies??? Under the Holding Foreign Companies Accountable Act, the SEC can ban foreign companies from trading ..." Wall Street Journal, 4/21/25 ... "Many investors would opt to SELL their stakes in Chinese firms if they are delisted"
March 10, 2025
including pre-funded warrants to purchase 1,404,988 shares of common stock at an offering price of $28.47 per pre-funded warrant with an exercise price of $0.01 per share. BEAM closed Friday at $1.23 to $28.48 with a pre-open indication of $2.57 or +0.02% to $31.05 Gross proceeds from the offering are expected to be approximately $500.0 million expected to close on or about 3/11/2525
February 18, 2025
35.739 M shares were priced at $4.30 with 13.88 M warrants priced at $4.029 Tuesday SLDB jumped +$1.27 to $5.30 The financing includes new and existing investors, including Adage Capital Partners LP, Bain Capital Life Sciences, Invus, Perceptive Advisors, RA Capital Management, TCGX, Venrock Healthcare Capital Partners, Vestal Point Capital, a U.S.-based life-sciences focused institutional investor, a major mutual fund and a large investment management firm.
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
